<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963597</url>
  </required_header>
  <id_info>
    <org_study_id>4889</org_study_id>
    <nct_id>NCT02963597</nct_id>
  </id_info>
  <brief_title>Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.</brief_title>
  <acronym>ASAP-HF</acronym>
  <official_title>Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein Healthcare Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Resmed Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein Healthcare Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of continuous positive airway pressure
      (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF)
      patients with obstructive sleep apnea (OSA). The study will also assess changes in functional
      parameters, biomarkers, and echocardiographic parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ASAP-HF study is a prospective, randomized, controlled, two-center, study with a parallel
      group design, with subjects randomized to either control (no APAP) or active treatment (APAP)
      in a 1:1 ratio. Group A (active): standard medical therapy plus treatment with continuous
      APAP for 48hrs, or Group B (control): standard medical therapy only.

      Many people who have heart failure (HF) also have sleep-disordered breathing (SDB), which is
      breathing irregularities during sleep. These irregularities may interrupt the sleep as well
      as increase the rate of progression of Heart Failure. The ASAP-HF study is being done to see
      if certain clinical outcomes are improved in acute decompensated heart failure (HF) patients
      with SDB by using a non-invasive breathing device continuously for a short period of time (48
      hours) while patient is still in the hospital. The device is called AirSense™ 10 AutoSet
      (AutoSet). It consists of an air flow generator, air tubing, an air humidifier, and a mask.
      As the patient breathe through the mask, the AutoSet monitors breathing.

      The primary objective of this pilot study is to evaluate the effect of continuous positive
      airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated
      heart failure (HF) patients with obstructive sleep apnea (OSA). The study will also assess
      changes in functional parameters, biomarkers, and echocardiographic parameters . This device
      is not currently used to diagnose sleep apnea and its utility is not well studied. This study
      will establish the utility of the device in diagnosing sleep apnea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">August 15, 2018</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>CPAP Device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Artery Systolic Pressure.</measure>
    <time_frame>48 hours</time_frame>
    <description>The primary objective of this pilot study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with severe obstructive sleep apnea (OSA). The study will also assess changes in functional parameters, biomarkers, and echocardiographic parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Parameters (6 Minute Walk Test) From Baseline to 48hrs</measure>
    <time_frame>48 hours</time_frame>
    <description>6-minute walk tests were performed on admission and repeated after 48 hours from the initial. The walked distance was measured in meters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to 48hrs</measure>
    <time_frame>48 hours</time_frame>
    <description>To compare changes in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) measured at baseline and compared to 48hrs after.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>1 year</time_frame>
    <description>The total stay in the hospital during the admission will be measured by days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Oxygenation.</measure>
    <time_frame>48 hours</time_frame>
    <description>Changes in arterial blood oxygenation will be compared via arterial blood gas analysis performed at baseline and after 48h to assess arterial pressure of oxygen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure Symptoms</measure>
    <time_frame>48 hours</time_frame>
    <description>Heart failure symptoms as assessed by the New York Heart Association scale (NYHA) classification at baseline and after 48 hours. NYHA scale ranges from Class I to IV. Higher classes are associated with worst outcomes.
Class I: No symptoms and no limitation in ordinary physical activity. Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity.Comfortable only at rest.
Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid Retention</measure>
    <time_frame>48 hours</time_frame>
    <description>Change in fluid retention as measured by weight at baseline and after 48 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>E/e' as an Assumption of LVEDP.</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of E/e' in 2D echocardiography as an assumption of LVEDP and PV acceleration time comparing baseline and after 48hrs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Sleep Apnea, Obstructive</condition>
  <condition>Hypertension, Pulmonary</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard medical therapy only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AirSense™ 10 AutoSet</intervention_name>
    <description>The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Therapy</intervention_name>
    <description>Standard medical therapy according to current guidelines.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or more

          2. Decompensated Congestive Heart Failure with systolic Pulmonary Artery pressures of ≥50
             mmHg (including Right Atrial pressure)

          3. Prior clinical diagnosis of heart failure

          4. Moderate to Severe predominately obstructive sleep disordered breathing documented by
             polygraphy with Apnea Hypopnea Index (AHI) ≥20e/h and 5% of the time spent &lt;90% O2 Sat
             (minimum 2hr recording time)

          5. Patient is able to fully understand study information and sign informed consent

        Exclusion Criteria:

          1. Chronic renal insufficiency (Hemodialysis or serum creatinine &gt; 2)

          2. Hemodynamically significant valvular disease

          3. Severe arthritis or inability to complete 6 Minute Walk Test

          4. Left Ventricular Assist Device/ heart transplant or hemodynamically unstable

          5. Patient taking any Pulmonary vasodilators, including home oxygen.

          6. Known diagnosis of Obstructive Sleep Apnea (OSA) and on active therapy

          7. 80% of the respiratory events being central/Cheyne-Stokes breathing

          8. Recent cardiac surgery (within 30 days of admission)

          9. Recent stroke (within 30 days of admission or with persistent neurological deficits)

         10. Severe Chronic Obstructive Pulmonary Disease defined as forced expiratory volume at
             one second (FEV1) &lt; 50%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein Healthcare Network</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Healthcare Network</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>North Rhine-Westphalia</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 10, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>March 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02963597/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02963597/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the inpatient clinical services of the Albert Einstein Medical Center Philadelphia (US) and from the Heart and Diabetes Center of North Rhine-Westphalia (Germany). Patients signed an informed consent for the study prior to any study-related procedure. Before randomization, all eligibility criteria were confirmed.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provides non-invasive ventilatory support to treat patients with sleep-disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in the sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.6" spread="11.5"/>
                    <measurement group_id="B2" value="64.9" spread="9.96"/>
                    <measurement group_id="B3" value="67.75" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <description>defined by weight (kg) / [height x height (m)]</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.7" spread="5.8"/>
                    <measurement group_id="B2" value="31.2" spread="4.2"/>
                    <measurement group_id="B3" value="30.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of heart failure according to EF (HFrEF/HFpEF)</title>
          <description>Heart failure with preserved ejection fraction/HFpEF (ejection fraction more than 45%).
Heart failure with reduced ejection fraction/HFrEF (ejection fraction less than 45%)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HFpEF</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HFrEF</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Active smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of COPD</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Diagnosis of COPD confirmed with PFTs</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No diagnosis of COPD or negative PFTs</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apnea-hypopnea index (AHI)</title>
          <description>Apnea-hypopnea index (AHI) obtained by polygraphy (ApneaLink Air device).</description>
          <units>events/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="8"/>
                    <measurement group_id="B2" value="34.3" spread="9.2"/>
                    <measurement group_id="B3" value="33.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulmonary Artery Systolic Pressure.</title>
        <description>The primary objective of this pilot study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with severe obstructive sleep apnea (OSA). The study will also assess changes in functional parameters, biomarkers, and echocardiographic parameters.</description>
        <time_frame>48 hours</time_frame>
        <population>Patients pulmonary artery systolic pressures were measured by transthoracic echocardiography (TTE) on admission and 48 hours after enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Pulmonary Artery Systolic Pressure.</title>
          <description>The primary objective of this pilot study is to evaluate the effect of continuous positive airway pressure (PAP) therapy on pulmonary arterial (PA) pressures in acute decompensated heart failure (HF) patients with severe obstructive sleep apnea (OSA). The study will also assess changes in functional parameters, biomarkers, and echocardiographic parameters.</description>
          <population>Patients pulmonary artery systolic pressures were measured by transthoracic echocardiography (TTE) on admission and 48 hours after enrollment.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="53.6" upper_limit="63.5"/>
                    <measurement group_id="O2" value="62.7" lower_limit="56.2" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" lower_limit="37.4" upper_limit="48.1"/>
                    <measurement group_id="O2" value="57.5" lower_limit="49.9" upper_limit="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Parameters (6 Minute Walk Test) From Baseline to 48hrs</title>
        <description>6-minute walk tests were performed on admission and repeated after 48 hours from the initial. The walked distance was measured in meters.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Parameters (6 Minute Walk Test) From Baseline to 48hrs</title>
          <description>6-minute walk tests were performed on admission and repeated after 48 hours from the initial. The walked distance was measured in meters.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.6" lower_limit="151.5" upper_limit="253.6"/>
                    <measurement group_id="O2" value="153.6" lower_limit="96.3" upper_limit="210.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.6" lower_limit="156.9" upper_limit="288.2"/>
                    <measurement group_id="O2" value="161.8" lower_limit="104.5" upper_limit="219.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to 48hrs</title>
        <description>To compare changes in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) measured at baseline and compared to 48hrs after.</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to 48hrs</title>
          <description>To compare changes in N-terminal pro-Brain Natriuretic Peptide (NT-proBNP) measured at baseline and compared to 48hrs after.</description>
          <units>picogram/mililiter</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1087.6" lower_limit="528.29" upper_limit="1646.9"/>
                    <measurement group_id="O2" value="1532.7" lower_limit="735.5" upper_limit="2329.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="466.5" lower_limit="258" upper_limit="675"/>
                    <measurement group_id="O2" value="1500.2" lower_limit="274.1" upper_limit="2726.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay</title>
        <description>The total stay in the hospital during the admission will be measured by days.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay</title>
          <description>The total stay in the hospital during the admission will be measured by days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="5.3" upper_limit="13"/>
                    <measurement group_id="O2" value="13.7" lower_limit="2.2" upper_limit="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Oxygenation.</title>
        <description>Changes in arterial blood oxygenation will be compared via arterial blood gas analysis performed at baseline and after 48h to assess arterial pressure of oxygen.</description>
        <time_frame>48 hours</time_frame>
        <population>Data was not available for all participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Oxygenation.</title>
          <description>Changes in arterial blood oxygenation will be compared via arterial blood gas analysis performed at baseline and after 48h to assess arterial pressure of oxygen.</description>
          <population>Data was not available for all participants.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.84" lower_limit="59.5" upper_limit="86.1"/>
                    <measurement group_id="O2" value="76.7" lower_limit="69.9" upper_limit="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="64.5" upper_limit="95.5"/>
                    <measurement group_id="O2" value="77.9" lower_limit="71.2" upper_limit="84.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Failure Symptoms</title>
        <description>Heart failure symptoms as assessed by the New York Heart Association scale (NYHA) classification at baseline and after 48 hours. NYHA scale ranges from Class I to IV. Higher classes are associated with worst outcomes.
Class I: No symptoms and no limitation in ordinary physical activity. Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity.Comfortable only at rest.
Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
        <time_frame>48 hours</time_frame>
        <population>Data was not available for participants after 48 hours. PI has left the institution; efforts to contact unsuccessful; data information not available for after 48hr time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Failure Symptoms</title>
          <description>Heart failure symptoms as assessed by the New York Heart Association scale (NYHA) classification at baseline and after 48 hours. NYHA scale ranges from Class I to IV. Higher classes are associated with worst outcomes.
Class I: No symptoms and no limitation in ordinary physical activity. Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III: Marked limitation in activity due to symptoms, even during less-than-ordinary activity.Comfortable only at rest.
Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
          <population>Data was not available for participants after 48 hours. PI has left the institution; efforts to contact unsuccessful; data information not available for after 48hr time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.9" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.2" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fluid Retention</title>
        <description>Change in fluid retention as measured by weight at baseline and after 48 hours.</description>
        <time_frame>48 hours</time_frame>
        <population>Data after 48 hours was not available for the participants of the study. PI has left the institution; efforts to contact unsuccessful; data information not available for after 48hr time point</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Fluid Retention</title>
          <description>Change in fluid retention as measured by weight at baseline and after 48 hours.</description>
          <population>Data after 48 hours was not available for the participants of the study. PI has left the institution; efforts to contact unsuccessful; data information not available for after 48hr time point</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="70.3" upper_limit="94.9"/>
                    <measurement group_id="O2" value="94.7" lower_limit="81.6" upper_limit="107.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>E/e' as an Assumption of LVEDP.</title>
        <description>Measurement of E/e' in 2D echocardiography as an assumption of LVEDP and PV acceleration time comparing baseline and after 48hrs.</description>
        <time_frame>48 hours</time_frame>
        <population>Data was not available for all the subjects at baseline and 48 hours after. PI has left the institution; efforts to contact unsuccessful; clarifying data information not available</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>E/e' as an Assumption of LVEDP.</title>
          <description>Measurement of E/e' in 2D echocardiography as an assumption of LVEDP and PV acceleration time comparing baseline and after 48hrs.</description>
          <population>Data was not available for all the subjects at baseline and 48 hours after. PI has left the institution; efforts to contact unsuccessful; clarifying data information not available</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="14.5" upper_limit="22.5"/>
                    <measurement group_id="O2" value="18.2" lower_limit="13.6" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" lower_limit="11.2" upper_limit="18.3"/>
                    <measurement group_id="O2" value="16.5" lower_limit="13.9" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Ejection Fraction in HFrEF</title>
        <description>Calculated ejection fraction in patients with heart failure with reduced ejection fraction (&lt;45%) at baseline and after 48 hours.</description>
        <time_frame>48 hours</time_frame>
        <population>Analyzing only patients with heart failure with reduced ejection fraction (&lt;45%).</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction in HFrEF</title>
          <description>Calculated ejection fraction in patients with heart failure with reduced ejection fraction (&lt;45%) at baseline and after 48 hours.</description>
          <population>Analyzing only patients with heart failure with reduced ejection fraction (&lt;45%).</population>
          <units>percentage (%)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="17.12" upper_limit="28.88"/>
                    <measurement group_id="O2" value="26.8" lower_limit="18.4" upper_limit="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After 48 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="26.6" upper_limit="32.9"/>
                    <measurement group_id="O2" value="26.7" lower_limit="18.3" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
AirSense™ 10 AutoSet: The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Standard medical therapy only.
Standard Medical Therapy: Standard medical therapy according to current guidelines.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PI has left the institution; efforts to contact unsuccessful; additional data information not available</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Sunil Sharma</name_or_title>
      <organization>Albert Einstein Healthcare Network</organization>
      <phone>2154566950</phone>
      <email>sharmasu@einstein.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

